

INLURIYO - (Eq 200MG Base ; Tablet)

Generic Name	IMLUNESTRANT TOSYLATE	Innovator	Eli Lilly
Dosage	Eq 200MG Base ; Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	INLURIYOTM is an estrogen receptor antagonist indicated for: • treatment of adults with ER-positive, HER2-negative, ESR1 mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.